Research programme: rheumatoid arthritis therapy - Myriad Pharmaceuticals
Alternative Names: MPI 126886; MPI 1882; MPI 44593; MPYS 333; MPYS 563; Rheumatoid arthritis therapy research programme - Myriad GeneticsLatest Information Update: 10 Aug 2007
At a glance
- Originator Myriad Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 10 Aug 2007 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 24 Apr 2006 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 26 May 2004 This programme is still in active development